Speakers: Dr. Adrian Sacher and Dr. Zhaolin Xu
Chaired by: Dr. Barbara Melosky
Date: July 17, 2020, 1:00 PM EDT / 10:00 AM PSTThis webinar has been made possible through sponsorship from Amgen
Dr. Zhaolin Xu is a pulmonary pathologist and cytopathologist at Queen Elizabeth II Health Sciences Centre in Halifax and a professor in the Department of Pathology at the Dalhousie University. Dr. Xu is also a cancer researcher who holds the position of Senior Scientist in the Beatrice Hunter Cancer Research Institute. Dr. Xu is the driving force to establish and implement mutiplexed molecular profiling and biomarker testing for lung cancer in Nova Scotia and Atlantic Canada. In addition Dr. Xu has actively involved in many other activities on the national and international stages. He is a Panel Member in the Lung National Cancer Pathology and Staging Multidisciplinary Expert Panel, and Network Member in the Pan-Canadian Lung Cancer Screening Network, CPAC. He is the Cancer Protocol Review Panel Member for pulmonary and mediastinum tumors in the College of American Pathologists. He holds memberships in the Correlative Sciences and Tumor Biology Committee and Lung Cancer Subcommittee in the Canadian Cancer Trial Group. He sits in the Medical Advisory Committee and is the Chair of the Research Committee in Lung Cancer Canada. He is also a member of the College of Advisors in Canadian Tissue Repository Network (CTRNet). In addition Dr. Xu sits in the National Lung Cancer Advisory Committees for many pharmacuitical companites. Dr. Xu established the QE II Lung Tumor Bank in 2005 and the bank is certified by the Canadian Tissue Repository Network (CTRNet). It is now the most comprehensive lung tumor bank in the country. Dr. Xu’s research interest includes studying molecular profiling and biomarkers in lung cancer and selecting patients to receive personalized targeted therapy. His research interest also includes lung cancer metastasis and early detection, as well as interstitial lung diseases.
Dr. Adrian Sacher Dr. Sacher is a staff medical oncologist at Princess Margaret Hospital and an assistant professor in the Departments of Medicine & Immunology at the University of Toronto. Dr. Sacher completed his medical degree at the University of Toronto and residency at the Toronto General Hospital and Princess Margaret Cancer Center. He has previously completed a fellowship in thoracic oncology at the Dana-Farber Cancer Institute and holds a master’s degree in clinical trial design, genomics and drug development from Harvard Medical School.
Dr. Sacher’s research focuses on novel immunotherapeutics including immune checkpoint inhibitors, immune agonists, vaccines and epigenetic therapy. He is primarily interested in understanding the mechanisms of primary and acquired resistance to immunotherapy and developing tissue and blood based biomarkers as well as humanized animal models to better understand the biology of anti-tumor immune responses. He has a particular interest in the immunobiology of KRAS mutant tumors and therapeutic strategies to address oncogene addicted cancers. He has significant previous translational research experience in both tissue genomics and the development of blood-based biomarkers including plasma genotyping.
Dr. Barbara Melosky is a professor of medicine at the University of British Columbia and a medical oncologist in Vancouver at the British Columbia Cancer Agency. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group. Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organizes the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.
For more information, please contact Robyn Leonard at firstname.lastname@example.org.